Search results for "BODIES"

showing 10 items of 2217 documents

6-thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn's disease.

2005

Background & Aims: Azathioprine is the gold standard for immunosuppressive therapy in Crohn's disease (CD) and its molecular mechanism of action is caused by the metabolite 6-thioguanosine triphosphate (TGTP). In this study we assessed the impact of TGTP levels for monitoring of azathioprine therapy. Methods: A novel, highly sensitive assay was established to measure levels of TGTP and its precursors 6-thioguanosine monophosphates and 6-thioguanosine diphosphates (TGDP) in red blood cells from 50 CD patients. The results were correlated with clinical outcome. Results: TGTP levels could be quantified in 47 patients and a subgroup of these patients showed significantly high levels of TGDP. 6-…

Adultmedicine.medical_specialtyErythrocytesMetaboliteAzathioprineInflammatory bowel diseaseGastroenterologyGuanosine Diphosphatechemistry.chemical_compoundCrohn DiseaseInternal medicineAzathioprinemedicineHumansCrohn's diseaseHepatologyThiopurine methyltransferasebiologybusiness.industryGastroenterologyAzathioprine therapyAntibodies MonoclonalThionucleotidesmedicine.diseaseInfliximabGuanine NucleotidesInfliximabRed blood cellmedicine.anatomical_structurechemistryImmunologybiology.proteinbusinessBiomarkersImmunosuppressive Agentsmedicine.drugClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
researchProduct

Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura

2020

Abstract Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare but life-threatening condition. In 2018, the nanobody caplacizumab was approved for the treatment of adults experiencing an acute episode of aTTP, in conjunction with plasma exchange (PEX) and immunosuppression for a minimum of 30 days after stopping daily PEX. We performed a retrospective, observational analysis on the use of caplacizumab in 60 patients from 29 medical centers in Germany during acute disease management. Caplacizumab led to a rapid normalization of the platelet count (median, 3 days; mean 3.78 days). One patient died after late treatment initiation due to aTTP-associated complications. In 2 patients with…

Adultmedicine.medical_specialtyExacerbationmedicine.medical_treatmentThrombotic thrombocytopenic purpuraMedizin030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineFibrinolytic AgentsInternal medicinemedicineHumansRetrospective StudiesAcquired Thrombotic Thrombocytopenic PurpuraPurpura Thrombotic Thrombocytopenicbusiness.industryImmunosuppressionRetrospective cohort studyHematologySingle-Domain Antibodiesmedicine.diseasePurpuraDisease PresentationCardiovascular and Metabolic Diseases030220 oncology & carcinogenesisCaplacizumabmedicine.symptombusiness
researchProduct

Virtopsy and Living Individuals Evaluation Using Computed Tomography in Forensic Diagnostic Imaging

2019

The applications of forensic radiology involve both Virtopsy both studies on living people - to demonstrate bone age, search for foreign bodies, such as voluntary injection of drug ovules or surgical sponges accidentally forgotten, to assess gunshot wounds, to evaluate injuries by road accidents, and cases of violence or abuse (both in adults and in children). Computed tomography is the most used imaging tool used in forensic pathology and its indications are mainly focused on cases of unnatural deaths or when a crime is suspected. It is preferred over the standard autopsy in selected cases, such as in putrefied, carbonized or badly damaged bodies; or as a preliminary evaluation in mass dis…

Adultmedicine.medical_specialtyForensic pathologyAutopsyComputed tomographyWounds Nonpenetrating030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineVirtopsyAge Determination by SkeletonMedical imagingHumansMedicineRadiology Nuclear Medicine and imagingChildmedicine.diagnostic_testbusiness.industryGeneral surgerySurgical SpongesForensic MedicineForeign BodiesForensic scienceForensic radiologyWounds GunshotAutopsyTomography X-Ray Computedbusiness030217 neurology & neurosurgerySeminars in Ultrasound, CT and MRI
researchProduct

Obstetric significance of anti-Jr(a) antibody.

2001

Abstract The first case in the English-language medical literature of anti-Jr a antibody during pregnancy in a Spanish woman is described. The few reported cases to date about this issue are reviewed, with advice as to an obstetric guideline to follow for pregnant women with this antibody. (Am J Obstet Gynecol 2001;184:75-6.)

Adultmedicine.medical_specialtyGestational AgeHemolysisAntibodiesPregnancyImmunopathologyHemolytic disease of the newborn (ABO)medicineHumansBlood TransfusionPregnancybiologyObstetricsbusiness.industryInfant NewbornPregnancy OutcomeObstetrics and GynecologyGuidelinemedicine.diseaseAmniotic FluidSurgeryA AntibodyCoombs TestBlood Group Incompatibilitybiology.proteinGestationFemaleAntibodybusinessMedical literatureAmerican journal of obstetrics and gynecology
researchProduct

Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study.

2003

Summary: Fabry disease is an X-linked glycosphingolipid storage disorder caused by a deficiency of α-galactosidase A. Affected patients experience debilitating neuropathic pain and have premature mortality due to renal failure, cardiovascular disease or cerebrovascular complications. The disease may be X-linked dominant, since most females heterozygous for Fabry disease are affected clinically. We evaluated the safety, efficacy and pharmacokinetics of agalsidase alfa (Replagal) administered intravenously to female patients with Fabry disease in an open-label, single-centre study. Fifteen severely affected patients received agalsidase alfa at 0.2 mg/kg every other week for up to 55 weeks. Ag…

Adultmedicine.medical_specialtyHeterozygoteAdolescentArthritisRenal functionKidneyGastroenterologyAntibodiesArthritis RheumatoidElectrocardiographyPharmacokineticsInternal medicineGeneticsmedicineHumansGenetics (clinical)Vascular diseasebusiness.industryTrihexosylceramidesEnzyme replacement therapymedicine.diseaseFabry diseaseRecombinant ProteinsSurgeryClinical trialIsoenzymesEchocardiographyalpha-GalactosidaseNeuropathic painMutationFabry DiseaseFemalebusinessJournal of inherited metabolic disease
researchProduct

Immunoblotting as a confirmatory test for antimitochondrial antibodies in primary biliary cirrhosis.

1993

Primary biliary cirrhosis is characterised by the presence of antimitochondrial antibodies which are directed against components of mitochondrial dehydrogenase complexes. The specificity of antimitochondrial antibodies for primary biliary cirrhosis as detected by immunoblotting was investigated. Commercially available preparations of pyruvate and oxo-glutarate dehydrogenases and beef-heart mitochondria were used as source of antigens. Sera from 47 primary biliary cirrhosis patients (46 of whom were antimitochondrial antibody positive by immunofluorescence), 16 non-primary biliary cirrhosis patients (antimitochondrial antibody positive by immunofluorescence), 23 liver-kidney microsomal antib…

Adultmedicine.medical_specialtyPathologyBiliary cirrhosisImmunoblottingFluorescent Antibody TechniquePyruvate Dehydrogenase ComplexBiologyImmunofluorescenceGastroenterologyMitochondria HeartPrimary biliary cirrhosisAntigenAntibody SpecificityInternal medicinemedicineAnimalsHumansKetoglutarate Dehydrogenase ComplexAutoantibodiesHepatitismedicine.diagnostic_testLiver Cirrhosis BiliaryGastroenterologyAutoantibodyMiddle AgedPyruvate dehydrogenase complexmedicine.diseaseMitochondriabiology.proteinCattleFemaleAntibodyResearch ArticleGut
researchProduct

Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Inn…

2007

To evaluate in a prospective multicenter trial the feasibility and clinical efficacy of the combination of alemtuzumab (Campath-1H) with the cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) regimen (CHOP-C) as the primary treatment for patients with peripheral T-cell lymphoma (PTCL), between January 2003 and December 2005, 24 consecutive patients with PTCL entered the study and received 8 CHOP courses. Alemtuzumab was added at 30 mg subcutaneously at day −1 initially to the first 4 courses (4 patients), and then to all 8 courses (20 patients). Complete remission (CR) was achieved in 17 (71%) patients, 1 had partial remission, and 6 had stable/progressive disease. At a median follo…

Adultmedicine.medical_specialtyVincristineAntibodies NeoplasmImmunologyKaplan-Meier EstimateCHOPAntibodies Monoclonal HumanizedBiochemistryGastroenterologyChemoimmunotherapyAntigens CDAntigens NeoplasmMulticenter trialInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansMulticenter Studies as TopicAlemtuzumabCyclophosphamideSocieties MedicalAgedGlycoproteinsDose-Response Relationship Drugbusiness.industryPralatrexateAntibodies MonoclonalLymphoma T-Cell PeripheralCell BiologyHematologyMiddle Agedmedicine.diseaseSurgeryRegimenCD52 AntigenItalyDoxorubicinVincristineAlemtuzumabPrednisonebusinessProgressive diseasemedicine.drug
researchProduct

Hysteroscopic removal of a gauze inadvertently retained in uterus for two years following caesarean section

2021

Despite the worldwide accomplishment of manual counting procedures of surgical textiles and instruments, cases of retained (forgotten) surgical items (RSIs) still occur. Gauzes are the most frequently RSIs, accounting for 90% of the cases because they are widely used. Approximately half of the cases occur in the context of general surgery procedures, fol- lowed by gynaecological – obstetrics surgery. The time inter- val between initial surgery, diagnosis and removal of the gauze is clinically relevant, as the morbidity and mortality are reduced if the foreign body is removed immediately after the offending operation. We report on a successful hysteroscopic identification and removal of a ga…

Adultmedicine.medical_specialtymedicine.medical_treatmentUterusHysteroscopy03 medical and health sciencesPostoperative Complications0302 clinical medicinePregnancymedicineHumansCaesarean sectionPregnancy030219 obstetrics & reproductive medicineHysteroscopicHysteroscopyC-SectionCesarean Sectionbusiness.industryGeneral surgeryUterusObstetrics and GynecologyForeign Bodiesmedicine.diseaseBandagesSettore MED/40 - GINECOLOGIA E OSTETRICIAmedicine.anatomical_structure030220 oncology & carcinogenesisFemalebusinessJournal of Obstetrics and Gynaecology
researchProduct

IL-15 in human visceral leishmaniasis caused byLeishmania infantum

2002

SummaryInterleukin (IL)-15 is a recently discovered cytokine with the ability to stimulate the proliferation activity of Th1 and/or Th2 lymphocytes. Here, we investigated the involvement of IL-15 in the immune response to Leishmania infantum infection by studying patients with visceral leishmaniasis (VL). We found that IL-15 is produced by leishmanial antigen (LAg)-stimulated peripheral blood mononuclear cells (PBMC) from active VL patients at a significantly higher level than those produced by cells from healed VL subjects or healthy controls. A significant increase in IL-15 serum blood levels was also observed in acute VL patients compared with healed ones. Furthermore, recombinant IL-15 …

Adultmedicine.medical_treatmentImmunologyAntigens ProtozoanLymphocyte ActivationInterferon-gammaTh2 CellsAntigenmedicineAnimalsHumansImmunology and AllergyLeishmania infantumInterleukin-15biologyAntibodies MonoclonalInterleukinOriginal ArticlesTh1 Cellsbiology.organism_classificationmedicine.diseaseInterleukin-12Recombinant ProteinsCytokineVisceral leishmaniasisInterleukin 15ImmunologyLeukocytes MononuclearInterleukin 12Leishmaniasis VisceralInterleukin-4Leishmania infantumCell activationClinical and Experimental Immunology
researchProduct

Characterization of epitopes recognized by Candida factor 1 and 9 antisera by use of Saccharomyces cerevisiae mnn mutants

1993

The use of Saccharomyces cerevisiae mnn mutants has facilitated the study of the epitopes recognized by antisera against several antigenic factors of the genus Candida (Candida Check; Iatron Laboratories, Tokyo, Japan). We have taken advantage of the very well characterized structure of the mannans of the different mnn mutants to compare their reactivities with the factor antisera used in the identification of different species of the genus Candida. The results of this study provide evidence that one of the antigenic determinants recognized by factor 1 antisera is the O-linked mannose chains of the cell wall mannoproteins, while that recognized by factor 9 antiserum is the alpha 1-6-linked …

AgglutinationAntigenicityAntigens FungalMolecular Sequence DataImmunologyMutantSaccharomyces cerevisiaeMannoseEnzyme-Linked Immunosorbent AssaySaccharomyces cerevisiaeBiologyMicrobiologyEpitopeMicrobiologyMannansEpitopeschemistry.chemical_compoundAntigenAnimalsAntibodies FungalCandidaMannanAntiserumImmune Serabiology.organism_classificationInfectious DiseasesCarbohydrate SequenceBiochemistrychemistryMutationParasitologyRabbitsResearch ArticleInfection and Immunity
researchProduct